XENETIC BIOSCIENCES, INC. Proceeds from Notes Payable
XENETIC BIOSCIENCES, INC. (XBIO) reported Proceeds from Notes Payable of $100.00 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-19.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2015-08-19
- XENETIC BIOSCIENCES, INC. proceeds from notes payable for the quarter ending 2013-11-30 was $160.00K.
| Period end | Proceeds from Notes Payable 1 month | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 7 month | Proceeds from Notes Payable 10 month | Proceeds from Notes Payable 19 month | Proceeds from Notes Payable 22 month |
|---|---|---|---|---|---|---|---|
| 2015-06-30 | $100.00K 10-Q · filed 2015-08-19 | ||||||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-19 | ||||||
| 2013-11-30 | $160.00K 10-Q · filed 2014-01-10 | ||||||
| 2013-05-31 | $212.81K 10-Q · filed 2013-07-17 | ||||||
| 2013-02-28 | $212.81K 10-Q · filed 2013-04-22 | ||||||
| 2012-05-31 | $212.81K 10-Q · filed 2012-07-16 | ||||||
| 2012-02-29 | $212.81K 10-Q · filed 2012-04-24 | ||||||
| 2011-08-31 | $212.81K 10-K · filed 2012-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |